News

INNO-105 is a naturally occurring peptide that has recently demonstrated anti-tumor activity in a phase I pancreatic cancer study. Innovive Pharmaceuticals licensed the worldwide rights to the drug

Each of this year’s Specialized Center of Research (SCOR) recipients will receive $1.25 million per year for five years, a total of $6.25 million. In addition, the society

The trial’s independent safety and efficacy monitoring committee (SEMC) observed a safety concern from trial data collected thus far and is in the process of evaluating the entire

Amiloride and spironolactone are diuretics or ‘water pills’ that have been available for many years but no longer get much attention from prescribing physicians. A study by Indiana

The results of the study, published in the October issue of Cancer Research, demonstrate that Calando’s proprietary delivery technology can deliver short interfering RNA (siRNA) to targeted cancer

Using Affymetrix GeneChip technology including the GeneChip Human Mapping 500K Array Set, Perlegen scientists will assay up to 675,000 unique genetic variations (also called single nucleotide polymorphisms or

The company also said that in an effort to advance Oxycyte through the clinical development process and secure phase II data rapidly, it has temporarily suspended patient enrollment

Under the terms of the acquisition all shares of Guilford were exchanged for 5.3 million shares of MGI Pharma stock plus $53.9 million in cash, which represents $3.75

The parties anticipate the collaboration will initially focus on vascular, orthopedic and general surgery indications. Under the terms of the agreement, Angiotech will make an upfront license execution